2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149345
    IRAK4-IN-24 2952533-54-7
    IRAK4-IN-24 (compound 16) is a potent IRAK4 inhibitor, with high clearance (Cl) and poor oral bioavailability. IRAK4-IN-24 can be used for research in inflammatory and autoimmune disorders.
    IRAK4-IN-24
  • HY-149355
    COX-2-IN-33 3049405-60-6
    COX-2-IN-33 (compound 5f) is a COX-2 inhibitor (IC50=45.5 nM), as well as a potential anti-inflammatory agent. COX-2-IN-33 inhibits in vivo pro-inflammatory cytokine production and keep gastric safety.
    COX-2-IN-33
  • HY-149365
    SIKs-IN-1 2927557-06-8
    SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, is a Salt-inducible kinases (SIKs) inhibitor. SIKs regulates the transformation of M1/M2 macrophages, involving in inflammation process. SIKs-IN-1 inhibits SIK activity, up-regulates anti-inflammatory cytokine IL-10, but down-regulates pro-inflammatory cytokine IL-12. SIKs-IN-1 shows excellent anti-inflammatory effects in a DSS-induced colitis model.
    SIKs-IN-1
  • HY-149386
    D3R/MOR antagonist 1 3033883-15-4
    D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (Ki: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism.
    D3R/MOR antagonist 1
  • HY-149387
    D3R/MOR antagonist 2 3033883-17-6
    D3R/MOR antagonist 2 (Compound 121) is a D3R/MOR antagonist (Ki: 361 nM and 85.2 nM respectively). D3R/MOR antagonist 2 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism.
    D3R/MOR antagonist 2
  • HY-149391
    PROTAC BTK Degrader-6 2767204-39-5
    PROTAC BTK Degrader-6 (Compound 15) is a PROTAC BTK degrader (DC50: 3.18 nM. PROTAC BTK Degrader-6 has anti-inflammatory activity, inhibits NF-κB activation, and inhibits the expression of pro-inflammatory cytokines (e.g. IL-1β, IL-6).
    PROTAC BTK Degrader-6
  • HY-14939A
    Vapitadine hydrochloride 279253-83-7
    Vapitadine hydrochloride (Compound 3a) is a selective, orally active and nonsedating antihistamine agent, which exhibits a good binding affinity with human cloned histamine H1 receptor with a Ki of 19 nM. Vapitadine hydrochloride decreases the histamine-induced lethality (ED50 is 0.056-1.2 mg/kg), antagonizes the cutaneous reactions to histamine (ED50 is 0.51-1.4 mg/kg) in rats.
    Vapitadine hydrochloride
  • HY-149425
    SIRT5 inhibitor 6 2834736-82-0
    SIRT5 Inhibitor 6 is a potent, substrate-competitive and selective SIRT5 inhibitor with an IC50 of 3.0 μM. SIRT5 Inhibitor6 has a therapeutic potential against septic AKI in vivo.
    SIRT5 inhibitor 6
  • HY-149426
    SIRT5 inhibitor 7 2951090-00-7
    SIRT5 inhibitor 7 (compound 58) is a substrate-competitive and selective SIRT5 inhibitor with anti-inflammatory activity. SIRT5 inhibitor 7 has renal protective effects and regulates protein succinylation and the release of pro-inflammatory cytokines. SIRT5 inhibitor 7 has in vivo activity in AKI mouse models of lipopolysaccharide (LPS) and cecal ligation/perforation (CLP)-induced sepsis-related acute kidney injury.
    SIRT5 inhibitor 7
  • HY-149472
    Anti-osteoporosis agent-4
    Anti-osteoporosis agent-4 (Compound 11h) inhibits differentiation of primary osteoclasts. Anti-osteoporosis agent-4 attenuates RANKL-induced osteoclastogenesis. Anti-osteoporosis agent-4 inhibits osteoclast formation with an IC50 value of 358.29 nM. Anti-osteoporosis agent-4 inhibits PI3K/AKT and IκBα/NF-κB signaling pathway activation.
    Anti-osteoporosis agent-4
  • HY-149485
    JNK2-IN-1 2998941-15-2
    JNK2-IN-1 (Compound J27) is a JNK2 inhibitor (Kds: 79.2 μM). JNK2-IN-1 has anti-inflammatory activity. JNK2-IN-1 decreases the release of TNF-α and IL-6 through inhibiting the activation of NF-κB/MAPK pathway. JNK2-IN-1 alleviates the symptoms of LPS-induced acute lung injury (ALI) and sepsis.
    JNK2-IN-1
  • HY-149493
    IHMT-PI3K-455 3047746-40-4
    IHMT-PI3K-455 (Compound 15u) is a potent, selective, orally active PI3Kγ/δ dual inhibitor with IC50s of 7.1 nM and 0.57 nM for PI3Kγ and PI3Kδ, respectively. IHMT-PI3K-455 suppresses the AKT phosphorylation. IHMT-PI3K-455 inhibits tumor growth by recruiting and activating more CD8+ killing T cells.IHMT-PI3K-455 is used in cancer research.
    IHMT-PI3K-455
  • HY-149498
    Carbonic anhydrase inhibitor 15
    Carbonic anhydrase inhibitor 15 (Compound 8) is a carbonic anhydrase inhibitor (Ki: 8.5 nM for hCA II). Carbonic anhydrase inhibitor 15 has analgesic effect.
    Carbonic anhydrase inhibitor 15
  • HY-149503
    4-Hydroxy nebivolol hydrochloride 2717115-85-8
    4-Hydroxy nebivolol (4-OH nebivolol) hydrochloride is an active β-blocking hydroxylated metabolite of Nebivolol (HY-B0203).
    4-Hydroxy nebivolol hydrochloride
  • HY-149517
    EGFR/BRAFV600E-IN-2
    EGFR/BRAFV600E-IN-2 (compound 3g) is a potential multi-target inhibitor of EGFR, BRAFV600E, and EGFRT790M, and an inducer of apoptosis. EGFR/BRAFV600E-IN-2 can activate caspase-3, 8, and Bax, and downregulate the anti-apoptotic protein Bcl2, inducing apoptosis. EGFR/BRAF V600E-IN-2 also has antioxidant activity and DPPH free radical scavenging potency.
    EGFR/BRAFV600E-IN-2
  • HY-149523
    Anticancer agent 157
    Anticancer agent 157 (compound 15) is a NO inhibitor (IC50=0.62 μg/mL) with anti-inflammatory and anticancer activities. Anticancer agent 157 can bind to iNOS (inducible NO synthase) and caspase 8, causing nuclear fragmentation and chromatin condensation, inducing apoptosis. Anticancer agent 157 inhibits HT29 colon cancer cells (IC50=2.45 μg/mL), Hep-G2 liver cancer cells (IC50=3.25 μg/mL), and B16-F10 murine melanoma cells (IC50=3.84 μg/mL).
    Anticancer agent 157
  • HY-149580
    NF-κB-IN-12
    NF-κB-IN-12 (compound 3h) is a potent NF-κB inhibitor, with an IC50 of 1.02 μM. NF-κB-IN-12 can be used for acute lung injury research.
    NF-κB-IN-12
  • HY-149644
    CB2R agonist 3 444331-43-5
    CB2R agonist 3 is an agonist of cannabinoid receptor 2 (CB2R), with EC50 of 0.37μM that plays an important role in immune system.
    CB2R agonist 3
  • HY-149647
    HD-2a 606148-05-4
    HA-2a can inhibit the JAK2/STAT3 pathway via downregulates circDcbld2 expression in RAW264.7 cells.
    HD-2a
  • HY-149654
    FAAH/cPLA2α-IN-1 1696401-38-3
    FAAH/cPLA2α-IN-1 is a dual inhibitor of FAAH and cPLA2α with IC50s of 32 and 47 nM, respectively.
    FAAH/cPLA2α-IN-1
Cat. No. Product Name / Synonyms Application Reactivity